U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07536282) titled 'Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection' on April 10.
Brief Summary: This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Persistent HPV16 Infection
Intervention:
BIOLOGICAL: NWRD09
Participants will receive 4 injections of NWRD09 via IM to the lateral deltoid region of the upper arm, at D1 (W0D1), D15 (W2D1), D29 (W4D1) and D85 (W12D1)
BIOLOGICAL:...